NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA

14h ago🟡 Routine Noise
Share𝕏inf

FDA agrees to Annovis Bio’s pooled safety data plan for buntanetap NDA submission.

What the company is saying

Annovis Bio, Inc. (NYSE:ANVS) is highlighting the U.S. FDA’s agreement with its Integrated Summary of Safety (ISS) plan for buntanetap, its lead investigational drug for Alzheimer’s and Parkinson’s diseases. The company emphasizes that this plan allows it to pool safety data from both AD and PD clinical trials, leveraging the drug’s common mechanism of action and similar safety profiles. Annovis details the inclusion of three randomized, double-blind, placebo-controlled studies and one open-label extension in the pooled analysis, naming each study by clinical trial identifier. The company’s narrative, delivered by President, Founder and CEO Maria Maccecchini, Ph.D., frames the FDA’s agreement as a key regulatory milestone enabling a robust safety database. Annovis makes clear that the NDA will be submitted after the DUET-AD data readout and that FDA’s agreement does not guarantee NDA acceptance or approval. The tone is confident but measured, with explicit acknowledgment that final approval depends on the full efficacy and safety review.

What the data suggests

The announcement confirms FDA agreement on Annovis’s plan to pool and standardize safety data from its Alzheimer’s and Parkinson’s disease clinical programs for buntanetap. The pooled analysis will draw from three completed or ongoing randomized, double-blind, placebo-controlled studies and one open-label extension, specifically: NCT05357989 (early PD, Phase 3, completed), NCT05686044 (mild to moderate AD, Phase 2/3, completed), NCT06709014 (DUET-AD, Phase 3, active), and NCT07284784 (OLE PD, active). Annovis anticipates that over 1,600 participants will have received buntanetap by the 6-month DUET-AD data readout, though this is a projected figure rather than a realised total. The FDA has provided recommendations on statistical methods, which Annovis will incorporate into its final ISS statistical plan and updated Study Data Standardization Plan. No efficacy or safety results are disclosed in this update, and there are no financial or operational KPIs provided. The only numerical figure is the anticipated participant count, which signals trial scale but not clinical or financial outcome.

Analysis

The announcement is factual and proportionate, focusing on the FDA's agreement to Annovis Bio's safety data pooling plan for buntanetap. The language is positive but not exaggerated, with clear distinctions between realised milestones (FDA agreement on ISS plan, completed and ongoing trials) and forward-looking intentions (updating the statistical plan, anticipated NDA submission). The company explicitly states that FDA's agreement does not guarantee approval, tempering expectations. No large capital outlay or immediate financial impact is disclosed, and the only numerical figure is a projected participant count, not a realised operational or financial metric. The tone is optimistic but not promotional, and there is no evidence of narrative inflation or overstatement relative to the actual progress described.

Risk flags

  • ●Regulatory risk remains high, as FDA’s agreement to the ISS plan does not guarantee acceptance or approval of the NDA. Final regulatory decisions will depend on the full efficacy and safety results from DUET-AD and the pooled analysis.
  • ●Clinical risk is present because no efficacy or detailed safety outcomes have been disclosed; the success of the NDA depends on positive results from ongoing and completed trials, which are not summarized here.
  • ●Execution risk exists around the integration and standardization of complex datasets from multiple trials, as well as timely incorporation of FDA’s statistical recommendations into the final ISS and Study Data Standardization Plan.
  • ●Forward-looking participant count (over 1,600) is an estimate and may not reflect actual enrollment or exposure at the time of NDA submission, which could impact the perceived robustness of the safety database.

Bottom line

This announcement signals regulatory progress for Annovis Bio as the FDA has agreed to its plan for pooling safety data from Alzheimer’s and Parkinson’s disease trials to support a buntanetap NDA. The company is preparing to submit the NDA after the DUET-AD data readout, projecting over 1,600 participants will have received the drug by that point. No clinical efficacy or safety results are disclosed, and the FDA’s agreement does not imply approval or even acceptance of the NDA. Investors should focus on the upcoming DUET-AD data readout as the next critical milestone, since regulatory value realization and any commercial opportunity hinge on those results. The most important takeaway is that while this is a necessary regulatory step, the investment case will depend on the strength of the forthcoming clinical data and the ultimate FDA decision.

Announcement summary

(NYSE: ANVS) Annovis Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has agreed to the company’s Integrated Summary of Safety (ISS) plan for buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The ISS plan includes a strategy to pool safety data from both AD and PD clinical studies and to integrate the pooled data at the level of standardized analysis datasets, supporting the company’s planned New Drug Application (NDA) for buntanetap. Annovis submitted a draft of the data presentation, integration, and calculation to the FDA, which also provided recommendations on the statistical methods for the integrated analysis. The company plans to incorporate these recommendations into its final ISS statistical plan and submit an updated Study Data Standardization Plan. The pooled analysis will include data from three randomized, double-blind, placebo-controlled studies and one open-label extension (OLE) study: the completed Phase 3 study in early PD (NCT05357989), the completed Phase 2/3 study in mild to moderate AD (NCT05686044), the active Phase 3 DUET-AD (NCT06709014), and the active OLE PD (NCT07284784). By the 6-month data readout from DUET-AD, Annovis anticipates that over 1,600 participants will have received buntanetap across the pooled studies. Maria Maccecchini, Ph.D., President, Founder and CEO of Annovis, stated that FDA’s agreement on pooling and presentation allows the company to bring safety data from both programs together into a single, extensive database and to build the safety package while DUET-AD and OLE PD are still ongoing. Annovis intends to submit the NDA following the data readout of DUET-AD. FDA’s agreement with the pooling strategy does not constitute approval of buntanetap and does not ensure that the NDA will be accepted for filing or approved. FDA will make those determinations based on its review of the complete application, including the efficacy and safety results of DUET-AD.

Disagree with this article?

Ctrl + Enter to submit